ArticleClinical case reports2026
Improvement of Severe Volume Dependent Airway Closure With Tezepelumab: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma may be complicated by airway remodeling, manifesting as higher symptom burden, airflow limitation and reduced treatment response. The effect of biologics on lung function changes remains uncertain. We report a 31-year-old man with severe uncontrolled asthma and chronic rhinosinusitis with nasal polyposis, characterized by frequent exacerbations, marked type 2 inflammation, and pronounced volume-dependent airway closure on spirometry with evidence of small airway dysfunction. Despite optimized high-dose inhaled therapy, disease control remained poor. Treatment with tezepelumab was initiated following multidisciplinary assessment. After 12 months, the patient achieved normalization of symptoms, biomarkers, lung function, and flow-volume loop morphology without any further exacerbations. This case highlights a striking functional recovery associated with thymic stromal lymphopoietin blockade and suggests a potential role for tezepelumab in modifying early airway remodeling beyond symptom control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.